Isabela
@isaisabelagap
Brazilian Hematologist (Rio de Janeiro).Bone Marrow Transplant Specialist by CEMO/INCA. ESO's Certificate of Competence in Lymphoma CCL6 #lymsm
You might like
𝐂𝐞𝐫𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐞 𝐨𝐟 𝐂𝐨𝐦𝐩𝐞𝐭𝐞𝐧𝐜𝐞 𝐢𝐧 𝐋𝐲𝐦𝐩𝐡𝐨𝐦𝐚 and #LyFEcourse Congrats to organizers, thank you F. Cavalli, E. Zucca,@frbertoni @AnastasiosStat2 @PWMJohnson @ESOncology
Grateful to @BloodJournal, co-authors, and @SWOG for making this #downwithdex piece possible! Dex 40mg weekly in #MMsm induction: 1️⃣ Not practical even for trial-enrolled patients 2️⃣ Does not improve PFS vs ⬇️ dex Twitter 🧵 once I’m back from #IMS24! ashpublications.org/blood/article/…
#Myeloma Paper of the Day: Cool paper from @RahulBanerjeeMD showing analysis of S0777 and S1211 @SWOG trial data that lowering the dose of dex during induction therapy did not have an impact on long-term outcomes like PFS & OS: pubmed.ncbi.nlm.nih.gov/39321347/. #mmsm
Ongoing diarrhea after CAR T? Think IEC-Colitis. But rule out other infectious causes of diarrhea before starting steroid. Scope and biopsy will be necessary. In refractory cases try Infliximab or Vedolizumab. Not Tocilizumab. nature.com/articles/s4140…
Nature is widely considered one of the most prestigious scientific journals in the world. Here is a template by Nature on how to craft a masterpiece abstract for your paper:
#Hematology Optimising treatment strategies in older patients with mantle cell #lymphoma - @TheLancet #lymsm #geriheme #frailty thelancet.com/journals/lance…
I am scared of using CART or bispecifics in myeloma with large volume disease: CRS, neurotoxicity, HLH, risk of death, and all kinds of complications are much higher. I’d rather control myeloma and get it to low volume before using these immunotherapy treatments. This is why…
CART vs Bispecific Antibodies for follicular lymphoma? CART👉better efficacy Bispec👉better safety Epcoritamab+R2 could change the debate with promising efficacy Amazing debate with @AnnaSureda5 at @COSTEMCongress
Just out: Guidelines for testing and reporting cytogenetic results in myeloma @BloodCancerJnl #OpenAccess Bookmark! Allows you to incorporate latest IMS/IMWG high risk criteria in practice. @lbaughn @RahulBanerjeeMD @Rfonsi1 nature.com/articles/s4140…
5/7 - Día y noche (2010): Está claro que no son simples cortos, hechos para entretener. Lo más importante que tienen, es su componente didáctico. Yo este lo pondría en todos los colegios. Todo tiene sus cosas buenas y sus cosas malas. La vida…♥️
David Scott’s @BCCancer algorithm for treatment of newly-diagnosed DLBCL based on recent Canadian recommendation for polatuzumab reimbursement for ABC-subtype DLBCL #lymsm #18ICML @AshAlizadeh
And a similar theme in the presentation of zanubrutinib for rrPCNSL in PRIZM+ @ProfChrisPFox #18icml. Curiously, two patients in 'SD' had ongoing response. Great correlative work occurring in this study trying to better define responsive disease on imaging (and impressive OS!)
Epco in 1st line frail/elderly patients. With this all (CR) or nothing pattern, including in 1st line, we should definitely understand the mechanism of resistance. And how to overcome it. Will it be t-cell fitness or microenviroment?
Many questions in #DLBCL frontline!! Is R-CHOP a good backbone? Should be trials molecularly driven? Is IPI a good prognostic tool for stratification? How will we choose therapy in the setting of multiple positive trials? Great talk by Dr Nowakowski at #ICML2025 #18ICML
Excellent presentation of UK experience of RESTART protocol results in #CART in DLBCL by Andrea Kuhnl. @ILROGTeam @icmlconf #radonc
My advance congratulations to Dr. Jesus San Miguel who will receive the @EHA_Hematology Lifetime Achievement Award Tomorrow at #EHA25 Dr. SanMiguel has made incredible contributions to the field. A close friend and mentor to me. I’m sorry to miss the ceremony.
remembering a very good day in the company of dear colleagues and two great examples: Tefferi and Rajkumar
¡¡Kudos to @QueraltSalas @hematoclinicbcn @hospitalclinic for the LBA at #EHA2025!! Looking forward to learning more about your collaborative work on “HCT FRAILTY SCALE (HCT-FS) FOR ASSESSING #FRAILTY IN ALLOGENEIC HSCT PATIENTS”!! @sehh_es @GETH_info #geriheme #hematology
Although angioimmunoblastic T-cell lymphoma often shows unusual lymphocyte variants, circulating clover-leaf B cells in this case mimic neoplastic T cells, potentially camouflaging an associated large B-cell lymphoma. ow.ly/iOJ050W11Aq #bloodwork #lymphoidneoplasia
Top 5 #ASCO25 myeloma abstracts. #5 Dara-KRd significantly higher MRD- rate versus KRd; 59% vs 36% — ADVANCE trial. One more RCT establishing quadruplets (when feasible) as standard of care for newly diagnosed myeloma @DrOlaLandgren @Myeloma_Doc meetings.asco.org/abstracts-pres…
United States Trends
- 1. Texas A&M 16.3K posts
- 2. South Carolina 15.9K posts
- 3. Marcel Reed 2,977 posts
- 4. Aggies 4,694 posts
- 5. Semaj Morgan N/A
- 6. College Station 2,329 posts
- 7. Nyck Harbor 1,848 posts
- 8. Elko 2,722 posts
- 9. Shane Beamer N/A
- 10. Jeremiyah Love 3,637 posts
- 11. Malachi Fields 1,764 posts
- 12. Mike Shula N/A
- 13. Northwestern 4,717 posts
- 14. Michigan 41.3K posts
- 15. Sellers 10.1K posts
- 16. TAMU 6,081 posts
- 17. #iufb 1,616 posts
- 18. #GoBlue 2,360 posts
- 19. Dylan Stewart N/A
- 20. #GoIrish 3,286 posts
You might like
-
Carlos Chiattone
@CarlosChiattone -
Mariana Guarana
@mariana_guarana -
Lucila Kerbauy
@lucila_kerbauy -
Guilherme Perini, MD
@GuiperiniMD -
Jacques Kaufman
@jacqueskaufman -
Wellington Fernandes
@wellingtonhemat -
Alan Skarbnik
@ASkarbnik -
Lucas Cantadori
@lucascantadori -
Thiago Carneiro
@thiagoxcarneiro -
Renato Cunha, M.D.-Ph.D.
@DrRenatoCunha -
Madson de Farias
@madsoncdefarias
Something went wrong.
Something went wrong.